Literature DB >> 23132749

Egr-1: new conductor for the tissue repair orchestra directs harmony (regeneration) or cacophony (fibrosis).

Swati Bhattacharyya1, Feng Fang, Warren Tourtellotte, John Varga.   

Abstract

Fibroblasts and myofibroblasts are the key effector cells executing physiological tissue repair leading to regeneration on the one hand, and pathological fibrogenesis leading to chronic fibrosing conditions on the other. Recent studies identify the multifunctional transcription factor early growth response-1(Egr-1) as an important mediator of fibroblast activation triggered by diverse stimuli. Egr-1 has potent stimulatory effects on fibrotic gene expression, and aberrant Egr-1 expression or function is associated with animal models of fibrosis and human fibrotic disorders, including emphysema, pulmonary fibrosis, pulmonary hypertension and systemic sclerosis. Pharmacological suppression or genetic targeting of Egr-1 blocks fibrotic responses in vitro and ameliorates experimental fibrosis in the skin and lung. In contrast, Egr-1 appears to act as a negative regulator of hepatic fibrosis in mouse models, suggesting a context-dependent role in fibrosis. The Egr-1-binding protein Nab2 is an endogenous inhibitor of Egr-1-mediated signalling and abrogates the stimulation of fibrotic responses induced by transforming growth factor-β (TGFβ). Moreover, mice deficient in Nab2 show excessive collagen accumulation in the skin. These observations highlight a previously unsuspected fundamental physiological function for the Egr-1-Nab2 signalling axis in regulating fibrogenesis, and suggest that Egr-1 may be a potential novel therapeutic target in human diseases complicated by fibrosis. This review summarizes recent advances in understanding the regulation and complex functional role of Egr-1 and its related proteins and inhibitors in pathological fibrosis.
Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23132749      PMCID: PMC3965177          DOI: 10.1002/path.4131

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  100 in total

1.  Egr-1 inhibits apoptosis during the UV response: correlation of cell survival with Egr-1 phosphorylation.

Authors:  R P Huang; Y Fan; I deBelle; Z Ni; W Matheny; E D Adamson
Journal:  Cell Death Differ       Date:  1998-01       Impact factor: 15.828

Review 2.  Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.

Authors:  Swati Bhattacharyya; Jun Wei; John Varga
Journal:  Nat Rev Rheumatol       Date:  2011-10-25       Impact factor: 20.543

3.  A peptide derived from endostatin ameliorates organ fibrosis.

Authors:  Yukie Yamaguchi; Takahisa Takihara; Roger A Chambers; Kristen L Veraldi; Adriana T Larregina; Carol A Feghali-Bostwick
Journal:  Sci Transl Med       Date:  2012-05-30       Impact factor: 17.956

4.  Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress.

Authors:  S F Yan; T Fujita; J Lu; K Okada; Y Shan Zou; N Mackman; D J Pinsky; D M Stern
Journal:  Nat Med       Date:  2000-12       Impact factor: 53.440

5.  A nerve growth factor-induced gene encodes a possible transcriptional regulatory factor.

Authors:  J Milbrandt
Journal:  Science       Date:  1987-11-06       Impact factor: 47.728

6.  A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells.

Authors:  J Yu; V Baron; D Mercola; T Mustelin; E D Adamson
Journal:  Cell Death Differ       Date:  2006-09-22       Impact factor: 15.828

7.  Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression.

Authors:  M Guha; M A O'Connell; R Pawlinski; A Hollis; P McGovern; S F Yan; D Stern; N Mackman
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

8.  Frequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma.

Authors:  S A Abdulkadir; J M Carbone; C K Naughton; P A Humphrey; W J Catalona; J Milbrandt
Journal:  Hum Pathol       Date:  2001-09       Impact factor: 3.466

9.  Novel mutants of NAB corepressors enhance activation by Egr transactivators.

Authors:  J Svaren; B R Sevetson; T Golda; J J Stanton; A H Swirnoff; J Milbrandt
Journal:  EMBO J       Date:  1998-10-15       Impact factor: 11.598

10.  Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation.

Authors:  Florian Bea; Erwin Blessing; Monica I Shelley; Jennifer M Shultz; Michael E Rosenfeld
Journal:  Atherosclerosis       Date:  2003-04       Impact factor: 5.162

View more
  58 in total

1.  Keratinocyte Microvesicles Regulate the Expression of Multiple Genes in Dermal Fibroblasts.

Authors:  Ping Huang; Jiarui Bi; Gethin R Owen; Weimin Chen; Anne Rokka; Leeni Koivisto; Jyrki Heino; Lari Häkkinen; Hannu Larjava
Journal:  J Invest Dermatol       Date:  2015-08-19       Impact factor: 8.551

2.  Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Cancer Invest       Date:  2018-11-05       Impact factor: 2.176

3.  Extensive survey of STAT6 expression in a large series of mesenchymal tumors.

Authors:  Elizabeth G Demicco; Paul W Harms; Rajiv M Patel; Steven C Smith; Davis Ingram; Keila Torres; Shannon L Carskadon; Sandra Camelo-Piragua; Jonathan B McHugh; Javed Siddiqui; Nallasivam Palanisamy; David R Lucas; Alexander J Lazar; Wei-Lien Wang
Journal:  Am J Clin Pathol       Date:  2015-05       Impact factor: 2.493

4.  Social descent with territory loss causes rapid behavioral, endocrine and transcriptional changes in the brain.

Authors:  Karen P Maruska; Lisa Becker; Anoop Neboori; Russell D Fernald
Journal:  J Exp Biol       Date:  2013-06-20       Impact factor: 3.312

Review 5.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

Review 6.  Promising new treatment targets in patients with fibrosing lung disorders.

Authors:  Martina Sterclova; Martina Vasakova
Journal:  World J Clin Cases       Date:  2014-11-16       Impact factor: 1.337

7.  MiR-150-5p retards the progression of myocardial fibrosis by targeting EGR1.

Authors:  Jie Shen; Wanhong Xing; Fangqi Gong; Wei Wang; Yufeng Yan; Yiying Zhang; Chunhong Xie; Songling Fu
Journal:  Cell Cycle       Date:  2019-05-23       Impact factor: 4.534

Review 8.  Friend or foe, the role of EGR-1 in cancer.

Authors:  Tong-Tong Li; Man-Ru Liu; Dong-Sheng Pei
Journal:  Med Oncol       Date:  2019-11-20       Impact factor: 3.064

9.  Inflammation, wound repair, and fibrosis: reassessing the spectrum of tissue injury and resolution.

Authors:  Eric S White; Alberto R Mantovani
Journal:  J Pathol       Date:  2013-01       Impact factor: 7.996

10.  Androgen deprivation therapy induces androgen receptor-dependent upregulation of Egr1 in prostate cancers.

Authors:  Bin Xu; Gusheng Tang; Chengwu Xiao; Linhui Wang; Qing Yang; Yinghao Sun
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.